金沙官网8331澳门
Latest results announcements and presentations金沙国际
金沙官网8331澳门
Capital markets event - Meet AZN management: ASCO 2020金沙官网8331澳门
1 June 2020
First-quarter 2020 results金沙官网8331澳门
29 April 2020
Full-year and Q4 2019 results金沙官网8331澳门
14 February 2020
Epidemiology data update金沙官网8331澳门
14 February 2020
金沙官网8331澳门
General investor presentation金沙官网8331澳门
24 December 2019
Investor science conference call: American Society of Hematology 2019金沙官网8331澳门
10 December 2019
Investor science conference call: American College of Rheumatology 2019金沙官网8331澳门
13 November 2019
Investor science conference call: American Society of Nephrology Kidney Week 2019金沙官网8331澳门
11 November 2019
Year-to-date and Q3 2019 Results金沙官网8331澳门
24 October 2019
Investor science conference call: European Society for Medical Oncology (ESMO) Congress 2019金沙官网8331澳门
30 September 2019
Investor science conference call: Farxiga's DAPA-HF trial at ESC 2019金沙官网8331澳门
1 September 2019
H1 2019 Results金沙官网8331澳门
25 July 2019
‘Meet AZN management’ at 2019 ASCO Annual Meeting金沙官网8331澳门
3 June 2019
Q1 2019 Results金沙官网8331澳门
26 April 2019
Collaboration on trastuzumab deruxtecan Investor conference call金沙官网8331澳门
29 March 2019
Full-Year 2018 Results金沙官网8331澳门
14 February 2019
金沙官网8331澳门
Year-end webcast for investors and analysts on China and Emerging Markets金沙官网8331澳门
13 December 2018
AHA Scientific Sessions 2018金沙官网8331澳门
12 November 2018
Year-To-Date and Q3 2018 Results金沙官网8331澳门
8 November 2018
H1 2018 Results金沙官网8331澳门
26 July 2018
AstraZeneca Investor Event at the 2018 ASCO Annual Meeting金沙官网8331澳门
1 June 2018
Q1 2018 Results金沙官网8331澳门
18 May 2018
Full-Year 2017 Results金沙官网8331澳门
2 February 2018
金沙官网8331澳门
Investor science event: Late-stage pipeline webcast金沙官网8331澳门
14 December 2017
Year-To-Date and Q3 2017 Results金沙官网8331澳门
9 November 2017
AstraZeneca Investor Science Event at ERS 2017金沙官网8331澳门
13 September 2017
AstraZeneca Investor Science Event at ESMO 2017金沙官网8331澳门
8 September 2017
H1 2017 Results金沙官网8331澳门
27 July 2017
General Investor presentation金沙官网8331澳门
16 June 2017
AstraZeneca Investor Science Event at 2017 ASCO Annual Meeting金沙官网8331澳门
5 June 2017
Q1 2017 Results金沙官网8331澳门
27 April 2017
Full-Year and Q4 2016 Results金沙官网8331澳门
2 February 2017
金沙官网8331澳门
Second year-end late-stage pipeline investor science webcast金沙官网8331澳门
15 December 2016
Year-to-date and Q3 2016 Results金沙官网8331澳门
10 November 2016
Investor Relations Benelux roadshow金沙官网8331澳门
8 September 2016
ERS Investor science webcast金沙官网8331澳门
7 September 2016
DNA Damage Response analyst science event金沙官网8331澳门
5 September 2016
H1 2016 Results金沙官网8331澳门
28 July 2016
AstraZeneca Investor Science Event at ASCO 2016金沙官网8331澳门
7 June 2016
Q1 2016 Results金沙官网8331澳门
29 April 2016
Full-Year and Q4 2015 Results金沙官网8331澳门
4 February 2016
J.P. Morgan Healthcare Conference 2016金沙官网8331澳门
13 January 2016
金沙官网8331澳门
Majority stake investment in Acerta Pharma金沙官网8331澳门
17 December 2015
Late-stage pipeline call金沙官网8331澳门
2 December 2015
American College of Rheumatology (ACR) 2015 Investor science conference call金沙官网8331澳门
11 November 2015
Acquisition of ZS Pharma金沙官网8331澳门
6 November 2015
Year-to-date and Q3 2015 results金沙官网8331澳门
5 November 2015
H1 2015 results金沙官网8331澳门
30 July 2015
American Society of Clinical Oncology (ASCO) 2015 Investor science event金沙官网8331澳门
1 June 2015
AstraZeneca Mölndal 金沙官网8331澳门
25 May 2015
First quarter results 2015 金沙官网8331澳门
24 April 2015
American College of Cardiology (ACC) 2015 Investor science conference call金沙官网8331澳门
16 March 2015
Fourth quarter and full year results 2014金沙官网8331澳门
5 February 2015
33rd J.P. Morgan Healthcare Conference金沙官网8331澳门
14 January 2015
金沙官网8331澳门
AstraZeneca Investor Day金沙官网8331澳门
18 November 2014
Third quarter and nine months results 2014 金沙官网8331澳门
6 November 2014
European Society for Medical Oncology (ESMO) 2014 金沙官网8331澳门
28 September 2014
Second quarter and half year results 2014 金沙官网8331澳门
31 July 2014
Strategic Transaction with Almirall in Respiratory Disease金沙官网8331澳门
30 July 2014
American Society of Clinical Oncology (ASCO) 2014金沙官网8331澳门
3 June 2014
American Thoracic Society (ATS) 2014 AstraZeneca Analyst briefing金沙官网8331澳门
20 May 2014
AstraZeneca strategy update 金沙官网8331澳门
6 May 2014
First quarter results 2014 金沙官网8331澳门
24 April 2014
Fourth quarter and full year Results 2013 金沙官网8331澳门
6 February 2014
J.P. Morgan Healthcare conference presentation金沙官网8331澳门
14 January 2014
金沙官网8331澳门
Global diabetes alliance analyst call 金沙官网8331澳门
19 December 2013
MedImmune R&D Roadshow 金沙官网8331澳门
7 November 2013
Third quarter and nine months results 2013 金沙官网8331澳门
31 October 2013
Second quarter and half year results 2013 金沙官网8331澳门
1 August 2013
American Society of Clinical Oncology (ASCO) 2013 briefing 金沙官网8331澳门
1 June 2013
First quarter results 2013金沙官网8331澳门
25 April 2013
AstraZeneca Investor Day金沙官网8331澳门
21 March 2013
Fourth quarter and full year results 2012金沙官网8331澳门
31 January 2013
Partnering for Growth: J.P. Morgan Healthcare Conference金沙官网8331澳门
9 January 2013
金沙官网8331澳门
Fostamatinib analyst briefing金沙官网8331澳门
15 November 2012
Third quarter and nine months results 2012金沙官网8331澳门
25 October 2012
Naloxegol educational presentation金沙官网8331澳门
18 October 2012
Second quarter and half year results 2012金沙官网8331澳门
26 July 2012
AstraZeneca business update金沙官网8331澳门
2 July 2012
R&D Roundtable金沙官网8331澳门
14 June 2012
First quarter results 2012金沙官网8331澳门
26 April 2012
Fourth quarter and full year results 2011金沙官网8331澳门
2 February 2012
30th Annual J.P. Morgan Healthcare Conference金沙官网8331澳门
11 January 2012
金沙官网8331澳门
Second quarter and half year results 2011金沙官网8331澳门
Fourth quarter and full year results 2010金沙官网8331澳门
金沙官网8331澳门
Second quarter and half year results 2010金沙官网8331澳门
Upcoming events金沙国际
J.P. Morgan European Healthcare Conference [Management] 金沙官网8331澳门
H1 2020 Results金沙官网8331澳门
SEC filings金沙国际
SEC filings are those documents that we are required to file by virtue of our listing on the New York Stock Exchange. They contain mainly financial information.
These documents are also available for viewing on the SEC website at www.sec.gov. The Company will send any holder of the Company’s securities, upon request, a hard copy of the Company’s complete audited financial statements free of charge. Requests may be made by writing to:
Company Secretary
AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
金沙国际
金沙官网8331澳门
金沙官网8331澳门
金沙官网8331澳门
金沙官网8331澳门
金沙官网8331澳门
金沙官网8331澳门
金沙国际
金沙官网8331澳门







